



Profitable Specialty Pharma Today & Growth Ahead

TSX: **CPH** | OTCQX: **CPHRF**

Investor Presentation | **March 2024**

FORWARD-LOOKING STATEMENTS & NON-IFRS MEASURES

All amounts are expressed in United States Dollars (“USD”) unless otherwise noted. This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, statements with respect to our objectives and goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective”, “hope” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.

By nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, the publication of negative results of clinical trials; our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire;

integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; product approval process by regulators which can be highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive with new competing product entrants; requirements for additional capital to fund future operations; products may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; the extent and impact of health pandemic outbreaks on our business; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; compliance with privacy and security regulation; our policies regarding product returns, allowances and chargebacks may reduce revenues; additional regulatory burden and controls over financial reporting; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; the potential

violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up.

We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the “Risk Factors” section of the Company’s most recently filed MD&A and the Company’s Annual Information Form, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

Lean Operating Model & Cash Generation Focus

Acquire & License Rx
medicines
Commercialize with
partners

Infrastructure-light
portfolio management
& commercialization

Developing our pipeline
in specialized therapeutic
areas

*Favourable
risk/return profile*



*Cost-effective,
cash generation focus*




*Selective low risk approach,
high unmet therapeutic
areas*




**OVER THE LAST 4 YEARS,
WE HAVE TRANSFORMED
OUR BUSINESS**

(US\$M)
Cash Balance Growth



(US\$M)
Income Before Tax



Recent 2022
brand extension
agreement



Distribution and supply
agreement with ANI
for Lipofen and
fenofibrate



Co-promotion
agreement
for Brinavess &
Aggrastat



Canadian Product Portfolio Demonstrated Revenue Growth

DERMATOLOGY PORTFOLIO

epuris[®]

Severe nodular acne
(Launched Jul 2013)

ozanex
ozenoxacin

Topical antibiotic for impetigo in patients
2 months and older (Launched Jan 2018)

actikerall[™]

Hyperkeratotic actinic keratosis
(Launched Feb 2016)

VANIQA[®]

Enzyme inhibitor for hair growth
(Launched Jun 2015)

HOSPITAL PORTFOLIO

BRINAVESS[®]

Recent onset Atrial Fibrillation (AF)
(Launched Oct 2018)



AGGRASTAT[®]

Acute Coronary Syndrome
(Launched Jul 2018)



SPECIALTY MEDICINE

Durela[®]
tramadol hydrochloride

Once-daily treatment of moderately severe pain
(Aralez Pharmaceuticals, Canada)

Growing Portfolio (USD, \$000s)



~\$12.7M

Product Revenue in 2023
(\$USD)



U.S. Licensing Portfolio Royalty Structure Delivers Earnings with Minimal Risk

Lipofen®

High cholesterol
(Kowa Pharmaceuticals, U.S.)



ConZip™

Once-daily treatment of moderately severe pain
(Vertical Pharmaceuticals, U.S.)



Absorica®

Severe nodular acne
(SUN Pharmaceuticals, U.S.)

~\$8.5M

Licensing Revenue in 2023
(\$USD)

STRONG FINANCIAL POSITION & EARNINGS

<i>(Millions of USD)</i>	2018	2019	2020	2021	2022	2023
Net revenue	22.7	22.5	21.6	21.9	20.7	21.2
Adjusted EBITDA	6.9	12.6	13.7	13.9	12.4	12.7
Net Income for period	0.5	3.2	4.5	7.8	26.6	14.9
Diluted income per share	0.02	0.12	0.17	0.29	1.03	0.59

\$39.8M

Cash at Dec 31, 2023


Debt-free

At Dec 31, 2023

Proven management

with track record of
generating earnings

STABILITY IN TOTAL REVENUE



Overall portfolio strength


Product revenue growth offsetting licensing revenue declines indicates overall portfolio strength

Stability going forward

U.S. products / licensing revenue have undergone loss of exclusivity; provides stability going forward

CAPITAL AVAILABLE TO DRIVE GROWTH

Uniquely positioned relative to specialty pharmaceutical peers, in a rising interest rate environment



Isotretinoin

epuris® Absorica®

\$38.0M

Canadian Isotretinoin Market¹

\$2.5B

U.S. Isotretinoin Market²

#1 Prescribed Oral
Isotretinoin by
Dermatologists

Sources:

¹ IQVIA CompuScript, Dec 2023 MAT

² Symphony Metys, Dec 2023 MAT

Markets Served



Canada, U.S., Mexico

Indication:

Nodular acne

Product Highlights:

- More consistent absorption under fed and fasted conditions
- Launched in Mexico in May 2023, Royalty style arrangement

Hospital Portfolio



BRINA VESS®

Recent onset Atrial Fibrillation (AF)
(Launched Oct 2018)

c\$3.1M

Market¹



AGGRASTAT®

Acute Coronary Syndrome
(Launched Jul 2018)

c\$1.0M

Market²

Sources:

¹ IQVIA CDH, Dec 2023 MAT

² IQVIA CDH

Markets Served



Indication:

Brinavess: Recent onset Atrial Fibrillation (AF)

Aggrastat: Anti-platelet used in Acute Coronary Syndrome

Product Highlights:

Aggrastat is an established treatment as a Glycoprotein IIb/IIIa Inhibitor

Lipofen[®]

USD **\$2.4B**
Market¹

Trusted Product in a
Large Market Segment

Sources:
¹ Symphony Metys, Dec 2023 MAT

cipher[™]
PHARMACEUTICALS

Markets Served



Indication:

High cholesterol

Product Highlights:

Stable mature product market

PRODUCT
CANDIDATE:
MOB-015

c\$91M
Annual Canadian market
for Onychomycosis

Current Market has only one
main product player

**Significant opportunity for
market disruption**

Sources:
IQVIA CompuScript Dec 2023 MAT

Acquired marketing
rights from:

Moberg Pharma AB (OMX:MOB)



Indication:

Onychomycosis (Nail fungus)

Advantage:

Topical application, improved safety profile, once weekly
treatment

Regulatory next step:

EU: Product approved, July 2023
US: Pivotal Phase III study underway, enrollment completed

Timeline:

US: Pivotal Phase III study results expected January 2025

PRODUCT
CANDIDATE:

CF-101 (piclidenoson)


c\$600M

Annual Canadian market for
plaque psoriasis treatments

c\$41M

Annual Canadian market for
moderate to severe plaque
psoriasis treatments

Sources:
Canadian Dermatology Association,
IQVIA CompuScript Dec 2023 MAT



Acquired marketing
rights from:

Can-Fite BioPharma (NYSE:CANF)



Indication:

Plaque psoriasis

Advantage:

Demonstrated increased efficacy with lower adverse events

Regulatory next step:

Phase III COMFORT study completed,
Pivotal Phase III study expected to start early 2024

Timeline

Pivotal trial results expected by 2026

PRODUCT
CANDIDATE:

DTR-001 (pre-clinical)

~200K+

Tattoo removal procedures
annually in the U.S.

Potentially **DISRUPTIVE
TECHNOLOGY** for a
world-wide problem

Acquired marketing
rights from:

Dalhousie University

Indication:

Topical treatment for the removal of tattoos

Advantage:

Non-invasive tattoo removal option;
replace/augment laser removal

Regulatory next step:

Proof of concept studies underway

CAPITAL STRUCTURE AND FINANCIAL SNAPSHOT

Financial Snapshot (C\$):

Market Capitalization (March 14, 2024)	\$171,048,365
Common Shares Outstanding	23,989,953
Stock Options and Share Awards	842,739
<i>% dilution</i>	3.5%
RSU's	351,202
<i>% dilution</i>	1.5%
Fully Diluted Shares	25,183,894
<i>% dilution</i>	5.0%

Analyst Coverage:

Leede Jones Gable	Doug Loe
Research Capital	Andre Uddin
Stifel	Justin Keyword

Stock Chart (C\$):



248%

2-year share appreciation

44%

insider holdings

Well below average dilution

WHY INVEST?



<h2>Light & lean operating model</h2>	<h2>Proven earnings & cash generation</h2>	<h2>Strong capital position</h2>	<h2>Robust pipeline</h2>
---	--	----------------------------------	--------------------------

